Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
I think it’s also important to remember that the scaled up BBI production capacity of millions per month is on top of the Cytiva production.
During the May results presentation Alistair said “Cytiva is a great partner with real scale...we will be putting in place other oem partners because the capacity cannot be supported with a single partner”
Whilst he doesn’t give indications of Cytiva’s capacity I would imagine it will be significant.
Just looking through this morning’s AstraZeneca RNS in which they state the following:
“ The Company's comprehensive pandemic response also includes rapid mobilisation of AstraZeneca's global research efforts to discover novel coronavirus-neutralising antibodies to prevent and treat progression of the COVID-19 disease, with the aim of reaching clinical trials in the next three to five months.”
As Avacta have already stated that they have affimers that will do exactly this, and we know that AS has been discussing deals, whether JV or licensing with big pharma, it looks like an excellent match. Hopefully we will hear news fairly soon.
A few days earlier, in the year end report they said this:
“ The Company aims to have a working laboratory test before the end of May and is now also transferring Affimer reagents to Cytiva to develop a rapid saliva test for the virus antigen suitable for mass screening of populations.”
Makes me think we should hear something this week.
RichKen,
I also read the report today and the figures truly are mind blowing. They predict approx:
$1.6 Bn p/a for POC LFT based on just a 5% market share
$0.3 Bn p/a for Adeptrix lab test
So roughly $2Bn p/a in sales.
Researching the Price/Sales ratio for Biotech in the US the Most recent figure I could find was 6.88 from January this year (higher than a lot of other industries) http://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/psdata.html
Applying this to the sales of $2Bn gives a potential market cap (were this a US listed stock) of $13.76Bn or £11.2Bn.
These figures don’t include the future prospects of the therapeutics division inc the latest ACE2 receptor news from last week.
Seems crazy to think this could happen over a reasonably short timescale.
Tony Blair interview just now-
EM - “it’s unrealistic - you’re talking about upping testing capacity to about a million a day - we’re not going to do that”
TB - “well you can do if you develop the ability to do at home testing, you could do that. Every person in the country is going to want to know what their status is in relation to this disease, have they had it, are they safe to go out. People will want to know.
EM -“but just not once, every week presumably”
TB “if you get the capability of doing this at scale then you may have to do it yes, regularly, but tell me the way out of it otherwise”
Multiple partners - news must be due soon on further collaborations.
"Avacta has quickly responded to the COVID-19 outbreak, generating multiple Affimer reagents that bind the SARS-COV-2 viral antigen within only four weeks, and working with multiple partners to address all three of these diagnostic markets."
They do sound very confident...
"The engineered characteristics of Affimer reagents offer benefits in LFA technology, addressing a number of drawbacks commonly seen when using antibodies in this platform for diagnostics. This includes issues of bottlenecks in assay development and production, cost to manufacture, signal sensitivity and specificity, difficult assay targets and assay shelf-life and storage"
According to this article Sona is a nasal swab - I assume to be transferred on to the LFD?
https://bondhealth.co.uk/blog/why-we-need-to-do-more-than-testing-for-covid-19
Super Cruise rollout - 7 models in 2021, 12 models in 2022
85% prefer Super Cruise in next vehicle
https://investor.gm.com/static-files/b3a8aa98-c503-4208-830c-78569ac34039
No DMS wins in the final quarter - still showing only 2 wins, customers 10 (FCA)? and 11(Ford)? Byton was customer 8 but they disappeared of the chart last year and haven't reappeared as yet. Could just be an error.
https://vp283.alertir.com/sites/default/files/report/vne_q4-2019_earnings_call_slides_05-feb-2020_final.pdf
You certainly need an awful lot of patience being a SEE investor. Many of us have been here years and are still waiting for the news that will propel us significantly upwards. I remain extremely confident and believe the turning point will come with a significant licensing deal, especially if the BOD make it clear that this eliminates the need for further dilution and shows a clear path to profit. That will remove much of the risk, and if followed by a nice juicy OEM contract we should see a re-rating. Each day is a day closer.
Whenever I start to get frustrated with SEE I remember one of my favourite quotes: When Jeff Bezos asked Warren Buffet "You're one of the richest guys in the world, and it's so simple. Why doesn't everyone just copy you?"
Buffet's answer was "Because nobody wants to get rich slow." Our patience will pay off in the end.
Speaking of data -
"Intel predicts the market for such data will be worth as much as $3.5 billion a year by 2030. McKinsey & Co. sees a much larger opportunity. A few years ago, the consulting firm said up to $750 billion of value would created from car-related data by 2030."
https://www.bloomberg.com/news/articles/2020-01-07/amazon-intel-and-ford-chase-automotive-data-dollars-at-ces
Finally been signed into law today:
https://twitter.com/etsc_eu/status/1199794690549309446?s=21